vs
Side-by-side financial comparison of Neuphoria Therapeutics Inc. (NEUP) and Osisko Development Corp. (ODV). Click either name above to swap in a different company.
Neuphoria Therapeutics Inc. is the larger business by last-quarter revenue ($15.0M vs $10.4M, roughly 1.4× Osisko Development Corp.).
Neuphoria Therapeutics Inc is a clinical-stage biopharmaceutical company focused on researching and developing innovative targeted therapies for unmet medical needs in neurological and psychiatric conditions, including anxiety, treatment-resistant depression, and other central nervous system disorders. Its core R&D efforts prioritize delivering safer, more effective treatment options for patient groups with limited existing care alternatives.
Osisko Development Corp. is a Canada-based mining exploration and development firm focused on high-grade gold and precious metal assets. It holds North American mineral projects, advancing them through exploration, feasibility study, and pre-production phases while adhering to sustainable mining standards.
NEUP vs ODV — Head-to-Head
Income Statement — Q3 FY2025 vs Q3 FY2024
| Metric | | |
|---|---|---|
| Revenue | $15.0M | $10.4M |
| Net Profit | $11.3M | — |
| Gross Margin | — | 3.2% |
| Operating Margin | 79.8% | -149.3% |
| Net Margin | 75.1% | — |
| Revenue YoY | — | — |
| Net Profit YoY | — | — |
| EPS (diluted) | $6.55 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 25 | $15.0M | — | ||
| Q3 24 | — | $10.4M | ||
| Q2 24 | — | $10.8M | ||
| Q2 23 | — | $22.0M | ||
| Q3 22 | — | $4.7M |
| Q1 25 | $11.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q2 23 | — | $-23.8M | ||
| Q3 22 | — | $-76.8M |
| Q1 25 | — | — | ||
| Q3 24 | — | 3.2% | ||
| Q2 24 | — | — | ||
| Q2 23 | — | 28.2% | ||
| Q3 22 | — | — |
| Q1 25 | 79.8% | — | ||
| Q3 24 | — | -149.3% | ||
| Q2 24 | — | -124.0% | ||
| Q2 23 | — | -241.5% | ||
| Q3 22 | — | -1940.8% |
| Q1 25 | 75.1% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q2 23 | — | -108.2% | ||
| Q3 22 | — | -1641.7% |
| Q1 25 | $6.55 | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q2 23 | — | — | ||
| Q3 22 | — | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $17.0M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $26.0M | — |
| Total Assets | $30.7M | — |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 25 | $17.0M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q2 23 | — | — | ||
| Q3 22 | — | — |
| Q1 25 | $26.0M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q2 23 | — | — | ||
| Q3 22 | — | — |
| Q1 25 | $30.7M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q2 23 | — | — | ||
| Q3 22 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $11.5M | — |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | 1.02× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 25 | $11.5M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q2 23 | — | — | ||
| Q3 22 | — | — |
| Q1 25 | 1.02× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q2 23 | — | — | ||
| Q3 22 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
